Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05404581 · ClinicalTrials.gov registry record · NA

Insula Neuromodulation for Chronic Neuropathic Pain

A NA study of Chronic Pain and Neuropathic Pain, sponsored by University of Virginia.

Recruiting
Registry status
NA
Development phase
12
Enrollment target
1
Study location

NCT05404581: Recruiting NA study of Chronic Pain and Neuropathic Pain, sponsored by University of Virginia.

NCT05404581 is a NA study of Chronic Pain and Neuropathic Pain that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 12 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05404581, a NA study of Chronic Pain and Neuropathic Pain, is actively recruiting participants, sponsored by University of Virginia.

RECRUITING
Registry status
NA
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

This study will comprehensively investigate the insula as a brain target for neuromodulation to treat chronic neuropathic pain.

Primary Outcome

Adverse event reporting will be collected throughout the study period. This will include neurological assessments by the study team postoperatively using the NIH Stroke Scale, MR imaging of implanted electrodes, comprehensive assessment of mood and cognition by a licensed psychologist, and vigilance for suicide with the asQ Screening Tool.

Interventions

  • DEVICE neuromodulation

Study Locations (1)

Virginia

  • University of Virginia - Charlottesville

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2022-11-01
Est. Completion 2027-06-29
Phase NA
University of Virginia

449 total trials

What NCT05404581 shows while recruiting

NCT05404581 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (98% lower).

The record links to 2 conditions, with Chronic Pain appearing as the primary indexed condition, and to 1 intervention - of which neuromodulation is the first listed.

NCT05404581 reports a single indexed study location in Virginia.

Frequently Asked Questions

What is clinical trial NCT05404581 about?

NCT05404581 is a clinical study titled "Insula Neuromodulation for Chronic Neuropathic Pain". This study will comprehensively investigate the insula as a brain target for neuromodulation to treat chronic neuropathic pain.

What is the current status of trial NCT05404581?

This trial is currently recruiting. It is a NA study. The enrollment target is 12 participants. The study started on 2022-11-01. Estimated completion is 2027-06-29.

What conditions does trial NCT05404581 study?

This clinical trial studies the following conditions: Chronic Pain, Neuropathic Pain.

What interventions are being tested in trial NCT05404581?

The interventions under investigation include: neuromodulation (DEVICE).

Who is sponsoring clinical trial NCT05404581?

This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05404581 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05404581's enrollment target sits among peer trials

12 287th of 301 higher than 13 of 301 other Chronic Pain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05404581, the US trial registry maintained by the National Library of Medicine. NCT05404581 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.